-
Content Related to Therapeutics
-
Launch of New Targeted Therapeutics will Drive Market Growth during the Forecast Period 2010–2017
Launch of New Targeted Therapeutics will Drive Market Growth during the Forecast Period 2010–2017 Oncology Therapeutics Market, Global Product Pipeline by Phase (%), 2011 Source: GBI Research, Company Websites, Clinicaltrials.gov, Company Annual Reports Product pipelines for all the therapeutic indications have targeted therapeutics in Phase III. The launch of some of the targete....Read more
Contributor: Pharma IQ News
Tags: oncology therapeutics | oncology therapeutics market | cancer
02/07/2012 12:00:00 AM EST -
Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Anxiety Disorders Therapeutics Market is Forecast to Show Steady Growth until 2017 GlobalData estimates that the global anxiety disorders therapeutics market was valued at $3,698m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 6.3% over the next seven years, to reach $5,689m by 2017. This steady growth is primarily attributed to only one product launch for generalized anx....Read more
Contributor: Pharma IQ News
Tags: anxiety disorders | anxiety disorders therapeutics | anxiety disorders treatment
10/20/2011 12:00:00 AM EDT -
£50 Million Technology and Innovation Centre in Cell Therapy to come to London
The Technology Strategy Board has announced further details about its Technology and Innovation Centre in Cell Therapy. The new centre will support the development and commercialisation of cell therapies and advanced therapeutics, as well as the underpinning technologies for manufacturing, quality control, safety and efficiency. It will receive £10 million per annum (up to £50 million ov....Read more
Contributor: Pharma IQ News
Tags: cell therapy | Technology Strategy Board | advanced therapeutics
12/05/2011 12:00:00 AM EST -
Janssen Creates New Division to Launch TMC435 and Help Conquer Hepatitis C in EMEA
Today sees the launch of Janssen Therapeutics EMEA, a division of Janssen Pharmaceutica NV, dedicated to bringing the investigational protease inhibitor TMC435 to hepatitis C patients in the EMEA region. Approximately 130-210 million people are infected with hepatitis C worldwide,1 with three to four million people newly infected each year.2 An estimated nine million people are infected with the dis....Read more
Contributor: Pharma IQ News
Tags: Janssen | Janssen Therapeutics EMEA | Janssen Pharmaceutica NV
04/19/2012 12:00:00 AM EDT -
Developing Clinical Trials for Oncology Part 3: Growth Trends in Oncology Therapeutics
More than ever clinical trials are more complicated and more difficult to run. Denis Mir, Senior Manager of Clinical Operations in Oncology at Eisai Global Clinical Development, shares his thoughts on the key drivers and innovations supporting growth in oncology therapeutics and the challenges
Tags: Denis Mir | Eisai Global Clinical Development | clinical trials oncology
-
Developing Clinical Trials for Oncology Part 4: The Recipe for Success
Biotechs have fuelled the oncology therapeutic area with many sucessful drugs. Denis Mir, Senior Manager of Clinical Operations in Oncology at Eisai Global Clinical Development, shares his thoughts about defining a recipe for success in oncology, designing the best clinical trials and partnering with
Tags: Denis Mir | Eisai Global Clinical Development | clinical trials
-
The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology Therapeutics
In this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about w hat trends he is witnessing in the improvement of safety assessments, his top 3 preclinical considerations in the discovery and
Contributor: Andrea Charles
Tags: predictive toxicology | preclinical considerations | computational biology
11/06/2012 12:00:00 AM EST -
Addex Therapeutics: Implications of Transporter Regulatory Themes in Drug Development
Sonia Poli, VP for Non Clinical Development at Addex Therapeutics, a small biotech built in Geneva explains how the new FDA and EMA guidelines will impact their business. She looks at the daily challenges they are faced with and stresses the importance of having highly valuated assays which will
Contributor: Niamh Madigan
Tags: Clinically relevant drug transporters | Sonia Poli | Addex Therapeutics
02/26/2013 12:00:00 AM EST -
Biotech Boom Drives Lyophilisation
Biological shift A growing biotechnology pipeline is fuelling the demand for lyophilisation technologies, and drug companies are looking to partner with contract manufacturing organisations (CMOs) which can assist them with lyophilising their increasing biological product range. In a recent interview with Pharma IQ, Tim Nicholls, director at eXmoor pharma concepts said: "All majo....Read more
Contributor: Andrea Charles
Tags: biotech | biopharmaceuticals | protein therapeutics
08/05/2010 12:00:00 AM EDT -
Pharmacovigilance and Outsourcing Case Study –Utilising a Fully Outsourced Model for Case Processing
United Therapeutics has undertaken a fully outsourced model for case processing. Maintaining the efficiencies the model was expected to provide requires establishing a functional integration of the vendor into the global pharmacovigilance system, and effective management of the relationship. Amber Scorah of Pharma IQ, interviewed Dr. Anthony Lassiter, Head of Global Drug Safety at United Therapeutics, fo....Read more
Contributor: Anthony Lassiter
Tags: Anthony Lassiter | United Therapeutics | pharmacovigilance
08/05/2011 12:00:00 AM EDT
A glossary of keywords, acronyms and general terminology used in day-to-day professional work, Pharma. If you would like to add to, edit or comment on this page, please drop us a line at info@pharma-iq.com





Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!